![Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c01953/asset/images/medium/jm2c01953_0018.gif)
Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry
![Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c01953/asset/images/medium/jm2c01953_0002.gif)
Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry
![Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis](https://www.mdpi.com/cancers/cancers-13-04863/article_deploy/html/images/cancers-13-04863-g005-550.jpg)
Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
![Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c01953/asset/images/large/jm2c01953_0007.jpeg)
Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry
![Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c01953/asset/images/medium/jm2c01953_0003.gif)
Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry
![Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis](https://www.mdpi.com/cancers/cancers-13-04863/article_deploy/html/images/cancers-13-04863-g001-550.jpg)
Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
![Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c01953/asset/images/medium/jm2c01953_0004.gif)
Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry
![Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis](https://www.mdpi.com/cancers/cancers-13-04863/article_deploy/html/images/cancers-13-04863-g002-550.jpg)
Cancers | Free Full-Text | Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
![The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41420-022-01009-1/MediaObjects/41420_2022_1009_Fig5_HTML.png)
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery
![The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41420-022-01009-1/MediaObjects/41420_2022_1009_Fig1_HTML.png)
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery
![The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41420-022-01009-1/MediaObjects/41420_2022_1009_Fig6_HTML.png)
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery
![The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41420-022-01009-1/MediaObjects/41420_2022_1009_Fig3_HTML.png)
The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA | Cell Death Discovery
![Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry Discovery of an Oral, Beyond-Rule-of-Five Mcl-1 Protein–Protein Interaction Modulator with the Potential of Treating Hematological Malignancies | Journal of Medicinal Chemistry](https://pubs.acs.org/cms/10.1021/acs.jmedchem.2c01953/asset/images/medium/jm2c01953_0006.gif)